Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management

PHASE4UnknownINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

October 15, 2021

Primary Completion Date

February 1, 2022

Study Completion Date

March 15, 2022

Conditions
Helicobacter Pylori
Interventions
DRUG

Naïve patients - ACO therapy

Naïve patients will receive classic triple therapy (amoxicillin, clarithromycin and lansoprazole) for 14 days

DRUG

Naïve patients - LNDL therapy

Naïve patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days

DRUG

Naïve patients - MNDL therapy

Naïve patients will receive Moxifloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days

DRUG

Treatment-experienced patients- LNDL therapy

Experienced patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days

DRUG

Treatment-experienced patients- MNDL therapy

Experienced patients will receive Moxifloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days

Trial Locations (1)

Unknown

RECRUITING

National Liver institute - Menoufia University, Shibīn al Kawm

Sponsors
All Listed Sponsors
collaborator

Future pharmaceutical industries

UNKNOWN

lead

National Liver Institute, Egypt

OTHER